Could Structured, Not Ad-Hoc, US FDA Flexibility Increase Rare Disease Development Certainty?

 
• By Bridget Silverman
  
/
The Haystack Project called for the FDA to clarify a route for rare disease flexibility instead of handling it case by case. (Shutterstock)
Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

SpotifyApple PodcastsWebsite

More from Review Pathways

More from Regulatory Pathways